Medication possession ratio (MPR), dose reduction and dose omission rates in the first three months of taking abemaciclib were compared. Baseline characteristics of patients in each group were compared with t-tests for continuous data and the chi square test for categorical data. Patients who received welcome kits (each welcome kit contains three boxes, each box contains ten 2mg tablets of loperamide) served as the intervention group patients who did not receive welcome kits served as the standard of care group. Methods: This is a retrospective study of patients throughout the United States with HR+, HER2- breast cancer who received abemaciclib from a large specialty pharmacy from Jto December 31, 2019. The purpose of this study is to determine whether adherence to abemaciclib differs for patients who receive loperamide in welcome kits versus those who do not receive loperamide in welcome kits. While the adverse events associated with abemaciclib have been well documented in clinical trials, it is unknown if adverse events, specifically diarrhea, impact adherence. Food and Drug Administration (FDA) approved abemaciclib to treat adult patients who have HR+ and HER2- advanced or metastatic breast cancer. Nearly 75% of patients with breast cancer have tumors that are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Background: According to the National Cancer Institute, breast cancer is the most common form of cancer in the United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |